Trial Profile
Potential discontinuation of tofacitinib following the achievement of LDA (low disease activity) in patients with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 20 Apr 2017 New trial record
- 12 Apr 2017 Results published in the Rheumatology